Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
67 hedge funds and large institutions have $88.5M invested in Neos Therapeutics, Inc in 2017 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 21 increasing their positions, 13 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
62% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 13
37% more funds holding
Funds holding: 49 → 67 (+18)
36% more capital invested
Capital invested by funds: $65M → $88.5M (+$23.5M)
20% more call options, than puts
Call options by funds: $403K | Put options by funds: $335K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$6.38M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$4.27M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$3.77M |
| 4 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$1.45M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.83M |
| 2 |
SBIA
Sheaff Brock Investment Advisors
Indianapolis,
Indiana
|
-$216K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$188K |
| 4 |
JP Morgan Chase
New York
|
-$99K |
| 5 |
FPF
FNY Partners Fund
New York
|
-$87K |
NEOS Hedge Fund Activity: Q2 2017 in Review
67 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q2 2017, worth a combined $88.5M — up 36% from $65M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NEOS positions and 4 closed out — a net gain of 18 holders — while 21 added to existing stakes and 13 trimmed.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $6.38M. The largest seller was Deerfield Management, cutting an estimated $4.83M.
- 67 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q2 2017, up from 49 in Q1 2017.
- Funds reported $88.5M of Neos Therapeutics, Inc stock for Q2 2017, up 36% quarter-over-quarter.
- 22 funds opened new Neos Therapeutics, Inc positions in Q2 2017 and 4 closed out, a net change of +18 holders.
- The largest Neos Therapeutics, Inc buyer in Q2 2017 was J. Goldman & Co, an estimated $6.38M added.
- The largest Neos Therapeutics, Inc seller in Q2 2017 was Deerfield Management, an estimated $4.83M sold.
Based on aggregated 13F filings for Q2 2017.